The Top Late-Breaking Trials: TRISCEND II, TRILUMINATE at 3 years, EuroSMR score, CLASP IID, OPERA-TAVI...

Session comprising selected PCR London Valves 2023 Late-Breaking Trial submissions in collaboration with EuroIntervention

Anchorperson: D. Capodanno

Spokesperson: S. Redwood

Summary

Discover the top late-breaking trials which were presented during PCR London Valves 2023:

TRISCEND II: A randomised trial of transcatheter tricuspid valve replacement vs medical therapy
Percutaneous edge-to-edge repair for tricuspid regurgitation: TRILUMINATE trial three-year outcomes
Transcatheter mitral valve-in-valve vs. redo surgical replacement for degenerated bioprostheses
Artificial intelligence derived risk score for mortality prediction in SMR-TEER: the EuroSMR score
One-year outcomes of transcatheter mitral repair from the CLASP IID trial
One-year clinical outcomes of TAVI with the latest iteration SE or BE devices: the OPERA-TAVI registry

Presentations available when logged in:

TRISCEND II: A randomised trial of transcatheter tricuspid valve replacement vs medical therapy
Percutaneous edge-to-edge repair for tricuspid regurgitation: TRILUMINATE trial three-year outcomes
Transcatheter mitral valve-in-valve vs. redo surgical replacement for degenerated bioprostheses
Artificial intelligence derived risk score for mortality prediction in SMR-TEER: the EuroSMR score
One-year outcomes of transcatheter mitral repair from the CLASP IID trial
One-year clinical outcomes of TAVI with the latest iteration SE or BE devices: the OPERA-TAVI registry